NDA 219070 · Crinetics
Palsonify
Paltusotine Hydrochloride · Oral
NovelOrphanCDER novel approval, Sep 25, 2025: To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Sep 25, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
3 Phase 3, 0 recruiting
FAERS reports
238
36 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 16, 2025.
PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option ( 1 ).
Mechanism: Similar to the natural hormone somatostatin, paltusotine suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. Paltusotine exerts its pharmacological activity via selective agonism (>4000-fold) at somatostatin receptor 2 (SSTR2) and exhibits little or no affinity for other SST receptor subtypes. Paltusotine inhibited cyclic adenosine monophosphate accumulation via human SSTR2 activation with an average drug (agonist) concentration that results in half-maximal response (EC 50 ) of 0.25 nM.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- PALSONIFY · PALTUSOTINE HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription
- PALSONIFY · PALTUSOTINE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Paltusotine" as an intervention, any sponsor and status, largest first.
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenPivotal-lookingActive, not recruiting
Crinetics Pharmaceuticals Inc.Industry
NCT07087054 · 141 participants (planned) · Start Nov 19, 2025 · Primary completion Aug 2027
Drug: Paltusotine; Placebo · For: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor and 6 more
Sites: Gilbert, Arizona; Newport Beach, California; New Haven, Connecticut · 72 sites in all
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)Pivotal-lookingTerminated
Crinetics Pharmaceuticals Inc.Industry
NCT05192382 · 111 participants · Start Dec 17, 2021 · Primary completion Jan 20, 2024
Drug: Paltusotine; Placebo · For: Acromegaly
Sites: Aurora, Colorado; Boston, Massachusetts; Columbus, Ohio · 57 sites in all
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of AcromegalyPivotal-lookingTerminated
Crinetics Pharmaceuticals Inc.Industry
NCT04837040 · 58 participants · Start May 12, 2021 · Primary completion Jul 10, 2023
Drug: Paltusotine; Placebo · For: Acromegaly
Sites: Los Angeles, California; Torrance, California; Baltimore, Maryland · 39 sites in all
Crinetics Pharmaceuticals Inc.Industry
NCT03789656 · 47 participants · Start Mar 12, 2019 · Primary completion Aug 3, 2020
Drug: Paltusotine · For: Acromegaly
Sites: Los Angeles, California; Chicago, Illinois; Boston, Massachusetts · 26 sites in all
Crinetics Pharmaceuticals Inc.Industry
NCT04261712 · 43 participants · Start Jan 29, 2020 · Primary completion Jun 30, 2026
Drug: Paltusotine · For: Acromegaly
Sites: Los Angeles, California; Chicago, Illinois; Boston, Massachusetts · 22 sites in all
Crinetics Pharmaceuticals Inc.Industry
NCT05361668 · 36 participants · Start Apr 22, 2022 · Primary completion Mar 7, 2024
Drug: Randomized: 40 mg Paltusotine; Randomized: 80 mg Paltusotine · For: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor and 6 more
Sites: Los Angeles, California; Newport Beach, California; Stanford, California · 35 sites in all
Crinetics Pharmaceuticals Inc.Industry
NCT03792555 · 13 participants · Start Mar 11, 2019 · Primary completion Jul 15, 2020
Drug: Paltusotine; Placebo · For: Acromegaly
Sites: Columbus, Ohio; Dallas, Texas; Curitiba, Brazil · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea52
- fatigue28
- product dose omission issue28
- nausea27
- abdominal discomfort25
- arthralgia21
- headache21
- abdominal pain16
- abdominal pain upper15
- gastrointestinal disorder14
- off label use14
- therapy interrupted14
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 2 |
| 2026 | 236 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.
Gadelha MR, Casagrande A, Strasburger CJ, et al. · J Clin Endocrinol Metab 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis.
Salvatori R, Colzani RM, Hummel N, et al. · J Clin Endocrinol Metab 2026 · Systematic Review, Network Meta-Analysis
- Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment.
Biller BMK, Casagrande A, Elenkova A, et al. · J Clin Endocrinol Metab 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
Gadelha MR, Gordon MB, Doknic M, et al. · J Clin Endocrinol Metab 2023 · Clinical Trial, Multicenter Study
- Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.
Madan A, Markison S, Betz SF, et al. · Pituitary 2022 · Clinical Trial, Phase I, Randomized Controlled Trial
- Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants.
Luo R, Madan A, Ferrara-Cook CT, et al. · Br J Clin Pharmacol 2025 · Clinical Trial, Phase I
Sponsor: Crinetics
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.